Estimaciones de analistas de Wall Street para Syndax Pharmaceuticals, Inc. (SNDX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-02 | $-0.51 | ||
| 2026-08-04 | $-0.55 | $-0.45 | -22.9% |
| 2026-04-30 | $-0.48 | $-0.59 | +18.6% |
| 2026-02-26 | $-0.78 | $-0.58 | -33.6% |
| 2025-11-03 | $-0.70 | $-0.74 | +5.4% |
| 2025-08-04 | $-0.83 | $-1.00 | +17.0% |
| 2025-05-05 | $-0.98 | $-1.04 | +5.8% |
| 2025-03-03 | $-1.10 | $-1.08 | -1.9% |
Ratios de valoración
| Precio / Valor contable | 101.04 |
| EV / EBITDA | -14.93 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $1.2M | $2.1M | $1.5M | $1.5M | $1.5M | $139.7M | 0 | 0 | $23.7M | $172.4M |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $826000 | $7.0M |
| Beneficio Bruto | $1.2M | $2.1M | $1.5M | $1.5M | $1.5M | $139.7M | 0 | 0 | $22.9M | $165.4M |
| I+D | $31.7M | $48.2M | $60.1M | $43.0M | $50.4M | $88.2M | $118.5M | $163.0M | $241.6M | $258.8M |
| Generales y Administrativos | $13.3M | $15.9M | $17.3M | $16.1M | $22.5M | $25.2M | $33.3M | $66.9M | $120.9M | $179.7M |
| Gastos Operativos | $45.0M | $64.1M | $77.4M | $59.1M | $72.9M | $113.5M | $151.8M | $230.0M | $362.5M | $438.5M |
| Beneficio Operativo | -$43.8M | -$62.0M | -$75.9M | -$57.5M | -$71.4M | $26.2M | -$151.8M | -$230.0M | -$339.7M | -$273.1M |
| EBITDA | -$43.7M | -$61.9M | -$73.9M | -$55.6M | -$70.3M | $26.9M | -$146.2M | -$209.1M | -$313.8M | -$251.6M |
| Gastos por Intereses | $956000 | $1.4M | $1.9M | 0 | $2.4M | $1.9M | $3.1M | $208000 | $4.9M | $33.8M |
| Beneficio Antes de Impuestos | -$44.5M | -$60.8M | -$74.0M | -$56.0M | -$73.2M | $24.9M | -$149.3M | -$209.4M | -$318.8M | -$285.4M |
| Impuestos | -$89000 | -$76000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$44.5M | -$60.8M | -$74.0M | -$56.0M | -$73.1M | $24.9M | -$149.3M | -$209.4M | -$318.8M | -$285.4M |
| BPA | $-3.04 | $-2.90 | $-2.92 | $-1.84 | $-1.77 | $0.48 | $-2.46 | $-2.98 | $-3.73 | $-3.29 |
| BPA Diluido | $-3.04 | $-2.90 | $-2.92 | $-1.84 | $-1.77 | $0.48 | $-2.46 | $-2.98 | $-3.73 | $-3.29 |
| Acciones en Circulación (Diluidas) | $14.6M | $21.0M | $25.4M | $30.5M | $41.3M | $52.1M | $60.8M | $70.4M | $85.6M | $86.6M |
Precio
| Precio | $17.28 |
| Capitalización | $1.5B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: AMLX · ATAI · CVAC · IMTX · INBX · NKTR · ORIC
Explorar sector: Healthcare · Biotechnology
Más secciones de SNDX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones